Salt Lake City – May 10, 2019 – PolarityTE, Inc., a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today data from two pilot studies on the use of its SkinTE™ product both showing successful closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period. The cases involved patients with lower extremity chronic wounds that were difficult to treat or had failed to heal with standard dressing care and conventional treatments, using a single application of SkinTE.
The data from each of the clinical case series was presented yesterday at the Symposium on Advanced Wound Care (SAWC) spring conference in San Antonio, TX. SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin.
The first study included wound closure rates for 11 DFU patients with Wagner 1 and Wagner 2 wounds. The second study included wound closure rates for five VLU patients. All patients had wounds resistant to standard dressing care. The chronic wounds in 10 of the 11 patients with DFUs and all five VLU patients demonstrated granulation, progressive epithelialization and closure within 12 weeks following a single application of SkinTE. The wounds remained closed, with no adverse reactions, during follow-up visits at least 14 weeks post initial SkinTE application. One DFU patient required treatment due to a non-related infection stemming from prior hardware in their foot, which required removal of the product before wound closure was achieved.
“Chronic lower extremity wounds, including DFUs and VLUs, represent an increasing and challenging burden on the health care system,” said Nikolai Sopko, MD, PhD, Chief Scientific Officer of PolarityTE. “Even when combined with advanced wound therapy, they are often some of the most difficult wounds to treat using the standard of care. Consequently, these studies are important in establishing SkinTE as a treatment option for patients with chronic wounds that don’t respond well to current treatment standards.”
“The pilot studies mirror the results we have seen from use of SkinTE by early adopters in our staged market release. We look forward to reporting on additional data related to these studies in the coming months,” said Dr. Sopko.
The studies are pilots for two multi-center, randomized controlled clinical trials evaluating SkinTE for DFUs and VLUs that the Company previously announced. Those clinical trials are currently enrolling patients. For additional information on PolarityTE’s clinical trials, visit: clinicaltrials.gov (identifiers: NCT03881254 and NCT03881267).
PolarityTE® is focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE® manufactures products from the patient's own tissue and uses the patient's own body to support the regenerative process. From a small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to regenerate the target tissues. PolarityTE®'s innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.